Cara Therapeutics, Inc. (CARA)
| Market Cap | 926.38M |
| Revenue (ttm) | 27.50M |
| Net Income (ttm) | -99.11M |
| Shares Out | 46.89M |
| EPS (ttm) | -2.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $18.56 |
| Previous Close | $18.05 |
| Change ($) | 0.51 |
| Change (%) | 2.83% |
| Day's Open | 18.06 |
| Day's Range | 18.04 - 18.78 |
| Day's Volume | 523,942 |
| 52-Week Range | 9.12 - 18.78 |
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
STAMFORD, Conn., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed ...
These 6 cannabis stocks show promise in the medical and recreational ends of the burgeoning marijuana sector, set to grow even more in 2021. The post 6 Cannabis Stocks to Buy as the U.S. Softe...
STAMFORD, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed ...
The opioid industry is an ~$50 billion annual business, but opioids are very harmful to the body and extremely addictive. CARA has a drug that is finishing its trials and expectation is that a...
- Topline data expected in first half of 2021 -
STAMFORD, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed ...
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2020 Results - Earnings Call Transcript
Cara (CARA) delivered earnings and revenue surprises of 48.53% and 86.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
– Conference call today at 4:30 p.m. ET –
STAMFORD, Conn., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed ...
Cara (CARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Results from global KALM-2 p ivotal Phase 3 t rial of KORSUVA ™ Injection in h emodialysis p atients with p ruritus to be presented –
ST GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus
- Cara to Host Conference Call Today at 8:30 am EDT -
STAMFORD, Conn., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed ...
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2020 Results - Earnings Call Transcript
Cara (CARA) delivered earnings and revenue surprises of 20.59% and 2.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
– Conference call today at 4:30 p.m. ET –
STAMFORD, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designe...
STAMFORD, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed...
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These marijuana stocks on the Nasdaq are top for value, growth, and performance for July 2020.
STAMFORD, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designe...
These companies are all surprising a few doubters lately.
Here are seven straightforward steps to help you invest in high-growth -- but high-risk -- marijuana stocks.
- Patient enrollment increased approximately 28% to maintain > 80% statistical power for primary endpoint and key registration endpoint of > 4-point improvement responder analysis -
These are the NASDAQ-listed marijuana stocks with the best value, fastest growth, and most momentum for June.
Cara Therapeutics (CARA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q1 2020 Results - Earnings Call Transcript
Cara (CARA) delivered earnings and revenue surprises of 1.59% and 67.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The company plans to submit its pruritis drug for FDA and EMA approval later this year.
As of late, it has definitely been a great time to be an investor in Cara Therapeutics.
STAMFORD, Conn. and ST. GALLEN, Switzerland, April 21, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP), today announced ...
- On track to report topline data for KALM-2 Phase 3 global trial of KORSUVA™ Injection in second quarter –
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q4 2019 Results - Earnings Call Transcript
Cara (CARA) delivered earnings and revenue surprises of 1.61% and -19.13%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
These stocks went in opposite directions in 2019. Will that trend continue this year?
These pharma stocks have gone in different directions in the last year, but both hold promise for forward-thinking investors.
Despite their differences, there's a lot of good things going on for both of these health companies.
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.
What does the future look like for this promising biotech stock?
STAMFORD, Conn., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a ...
Small-cap stocks have been subpar performers of late, but that weakness has only made the opportunity more compelling.
These two companies could be headed in vastly different directions in 2020.
About CARA
Cara Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated ... [Read more...]
| Industry Biotechnology | IPO Date Jan 31, 2014 |
| CEO Derek Chalmers | Employees 76 |
| Stock Exchange NASDAQ | Ticker Symbol CARA |
Financial Performance
In 2019, CARA's revenue was $19.89 million, an increase of 47.64% compared to the previous year's $13.47 million. Losses were -$106.37 million, 43.7% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for CARA stock is "Buy." The 12-month stock price forecast is 33.13, which is an increase of 78.50% from the latest price.